Daptacel market seen expanding on vaccination demand

The Daptacel vaccine market is projected to keep growing through the forecast period as childhood immunization programs, infectious disease pressure and travel-related disease risk support demand. North America is expected to hold the largest regional share in 2025, according to The Business Research Company.

Why it matters: - Daptacel protects children against diphtheria, tetanus and pertussis, making it part of routine pediatric disease prevention. - Rising infectious disease pressure and broader immunization efforts are supporting long-term vaccine demand. - The market outlook matters for public health systems, pediatric providers and vaccine planning as coverage needs expand.

What happened: - The Business Research Company released a market outlook on Daptacel on November 2, 2026. - The report says the Daptacel market has grown steadily in recent years. - The report projects continued expansion over the forecast period. - North America is projected to hold the largest Daptacel market share in 2025.

The details: - Daptacel is a combination vaccine for children under 7 years old. - The vaccine is typically given from 6 weeks through 6 years old as part of the standard immunization schedule. - Historical growth has been supported by established childhood vaccination programs, diphtheria outbreaks, public health immunization mandates, the safety record of DTaP vaccines and school-entry vaccination requirements. - Future growth is expected to be driven by broader pediatric healthcare access, stronger disease surveillance, better vaccine delivery infrastructure, global immunization campaigns and higher parent awareness of childhood immunizations. - Forecast-period trends include stronger pediatric immunization initiatives, wider routine vaccine coverage, better knowledge of pertussis prevention, broader adoption of combination vaccines and government support for early childhood immunization. - The report says rising infectious disease prevalence worldwide is a major growth driver. - The report defines infectious diseases as illnesses caused by bacteria, viruses, fungi or parasites that spread through human contact, insect vectors, contaminated surfaces or food, air transmission, bodily fluids and direct contact with infected people. - Globalization, climate change, antibiotic resistance, poor sanitation and vaccine coverage gaps have accelerated pathogen spread. - In August 2024, the UK Health Security Agency reported that England recorded 328 diphtheria cases from 278 individuals in 2023, up from 253 cases in 2022. - International travel and mobility are also supporting demand for the vaccine. - Eurostat reported in October 2024 that the European Union recorded nearly 2.9 billion nights spent in accommodations in 2023, including 1.6 billion nights from international visitors. - Eurostat also said 15.6% of international guest nights came from travelers outside Europe, up from 12.6% the prior year. - The report covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa in addition to North America. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The report offers a free sample and a full report on The Business Research Company website. - More information is available in the sample report and the full market report.

Between the lines: - The report ties vaccine-market growth to both routine childhood immunization and broader cross-border disease risk. - Diphtheria case increases in England and higher international travel volumes point to demand drivers beyond domestic pediatrics alone. - North America's projected lead suggests mature healthcare infrastructure and vaccination uptake remain central to near-term market strength.

What's next: - The market is expected to keep expanding as immunization campaigns broaden and delivery systems improve. - Combination vaccines and early-childhood government support are likely to remain important growth themes. - The report suggests future demand will track both disease surveillance trends and travel-related exposure risks.